JP2014530866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530866A5 JP2014530866A5 JP2014537234A JP2014537234A JP2014530866A5 JP 2014530866 A5 JP2014530866 A5 JP 2014530866A5 JP 2014537234 A JP2014537234 A JP 2014537234A JP 2014537234 A JP2014537234 A JP 2014537234A JP 2014530866 A5 JP2014530866 A5 JP 2014530866A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- condition
- disorders
- pharmaceutical composition
- pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 75
- 201000010099 disease Diseases 0.000 claims description 57
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 18
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 15
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 12
- 230000029663 wound healing Effects 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- 102000004452 Arginase Human genes 0.000 claims description 9
- 102100030356 Arginase-2, mitochondrial Human genes 0.000 claims description 9
- 101710186578 Arginase-2, mitochondrial Proteins 0.000 claims description 9
- 108700024123 Arginases Proteins 0.000 claims description 9
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims description 9
- 208000007502 anemia Diseases 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 208000014674 injury Diseases 0.000 claims description 8
- 208000028867 ischemia Diseases 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 6
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 6
- 208000019693 Lung disease Diseases 0.000 claims description 6
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 210000001185 bone marrow Anatomy 0.000 claims description 6
- 230000004064 dysfunction Effects 0.000 claims description 6
- 201000002491 encephalomyelitis Diseases 0.000 claims description 6
- 230000002949 hemolytic effect Effects 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 6
- 230000002458 infectious effect Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 6
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 5
- 208000015891 sexual disease Diseases 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 208000037905 systemic hypertension Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 241000321096 Adenoides Species 0.000 claims description 3
- 208000000230 African Trypanosomiasis Diseases 0.000 claims description 3
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 3
- 241000222122 Candida albicans Species 0.000 claims description 3
- 206010007134 Candida infections Diseases 0.000 claims description 3
- 208000024699 Chagas disease Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 241000700721 Hepatitis B virus Species 0.000 claims description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 208000002260 Keloid Diseases 0.000 claims description 3
- 206010023330 Keloid scar Diseases 0.000 claims description 3
- 208000004554 Leishmaniasis Diseases 0.000 claims description 3
- 206010027527 Microangiopathic haemolytic anaemia Diseases 0.000 claims description 3
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims description 3
- 241000721454 Pemphigus Species 0.000 claims description 3
- 208000008601 Polycythemia Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 claims description 3
- 208000003441 Transfusion reaction Diseases 0.000 claims description 3
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 210000002534 adenoid Anatomy 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 230000001363 autoimmune Effects 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 208000005980 beta thalassemia Diseases 0.000 claims description 3
- 208000022806 beta-thalassemia major Diseases 0.000 claims description 3
- 201000003984 candidiasis Diseases 0.000 claims description 3
- 230000002612 cardiopulmonary effect Effects 0.000 claims description 3
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 208000010643 digestive system disease Diseases 0.000 claims description 3
- 230000003176 fibrotic effect Effects 0.000 claims description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 3
- 208000007475 hemolytic anemia Diseases 0.000 claims description 3
- 208000009601 hereditary spherocytosis Diseases 0.000 claims description 3
- 208000029080 human African trypanosomiasis Diseases 0.000 claims description 3
- 201000001881 impotence Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
- 210000001117 keloid Anatomy 0.000 claims description 3
- 208000017169 kidney disease Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 230000002107 myocardial effect Effects 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 claims description 3
- 208000028169 periodontal disease Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000007056 sickle cell anemia Diseases 0.000 claims description 3
- 201000002612 sleeping sickness Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 208000027006 Tonsillar disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 230000010410 reperfusion Effects 0.000 claims 5
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000017228 Gastrointestinal motility disease Diseases 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000002741 palatine tonsil Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 22
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 206010059245 Angiopathy Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161548939P | 2011-10-19 | 2011-10-19 | |
| US61/548,939 | 2011-10-19 | ||
| PCT/US2012/060789 WO2013059437A1 (en) | 2011-10-19 | 2012-10-18 | Inhibitors of arginase and their therapeutic applications |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530866A JP2014530866A (ja) | 2014-11-20 |
| JP2014530866A5 true JP2014530866A5 (enExample) | 2015-12-03 |
| JP5993459B2 JP5993459B2 (ja) | 2016-09-14 |
Family
ID=47116482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014537234A Active JP5993459B2 (ja) | 2011-10-19 | 2012-10-18 | アルギナーゼ阻害剤およびそれらの治療用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9266908B2 (enExample) |
| EP (1) | EP2768491B1 (enExample) |
| JP (1) | JP5993459B2 (enExample) |
| CN (1) | CN104244932B (enExample) |
| AU (1) | AU2012326109A1 (enExample) |
| BR (1) | BR112014009415B1 (enExample) |
| CA (1) | CA2852685C (enExample) |
| IL (1) | IL232113A (enExample) |
| MX (1) | MX343534B (enExample) |
| WO (1) | WO2013059437A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012027034B1 (pt) | 2010-04-22 | 2020-10-13 | Mars, Incorporated | compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto |
| RS54750B1 (sr) | 2010-10-26 | 2016-10-31 | Mars Inc | Borati kao inhibitori arginaze |
| AU2012326109A1 (en) | 2011-10-19 | 2014-05-29 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| US10800751B2 (en) * | 2013-08-23 | 2020-10-13 | Virginia Commonwealth University | Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease |
| RU2574025C2 (ru) * | 2014-04-15 | 2016-01-27 | Государственное Научное Учреждение Научно-исследовательский институт ветеринарии Восточной Сибири Россельхозакадемии | Препарат для лечения острых желудочно-кишечных болезней новорожденных ягнят |
| PL410665A1 (pl) | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| WO2016210106A1 (en) | 2015-06-23 | 2016-12-29 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| CA3000996A1 (en) * | 2015-10-05 | 2017-04-13 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
| DK3368541T3 (da) | 2015-10-30 | 2020-06-29 | Calithera Biosciences Inc | Sammensætninger og metoder til inhibiering af arginaseaktivitet |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| US11291674B2 (en) | 2016-11-08 | 2022-04-05 | Calithera Biosciences, Inc. | Arginase inhibitor combination therapies |
| EP3842442B1 (en) | 2016-12-22 | 2023-11-01 | Precision Pharmaceuticals, Inc. | Compositions and methods for inhibiting arginase activity |
| CN108794517B (zh) * | 2017-04-27 | 2021-03-30 | 南京谷睿生物科技有限公司 | 一种精氨酸酶抑制剂及其制备方法与用途 |
| US10494339B2 (en) | 2017-05-12 | 2019-12-03 | Calithera Biosciences, Inc. | Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide |
| CA3073116A1 (en) * | 2017-08-16 | 2019-02-21 | Avalon Polytom (Hk) Limited | Compositions and methods for amino acid depletion therapy |
| EP3743510A1 (en) | 2018-01-28 | 2020-12-02 | Universite De Geneve | Arginase suppression for cancer treatment |
| US12054500B2 (en) | 2018-03-05 | 2024-08-06 | Arcus Biosciences, Inc. | Arginase inhibitors |
| WO2019186497A1 (en) | 2018-03-29 | 2019-10-03 | Oncoarendi Therapeutics S.A. | Dipeptide piperidine derivatives |
| US11274111B2 (en) | 2018-06-20 | 2022-03-15 | Merck Sharp & Dohme Corp. | Arginase inhibitors and methods of use |
| CN109053496B (zh) * | 2018-08-09 | 2020-10-20 | 吉尔生化（上海）有限公司 | 一种3-Boc-氨甲基环丁酮的合成方法 |
| WO2020102646A2 (en) | 2018-11-16 | 2020-05-22 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| CA3120718A1 (en) * | 2018-11-21 | 2020-05-28 | Black Belt Tx Ltd | Inhibitors of arginase |
| PH12021551902A1 (en) | 2019-02-08 | 2022-08-01 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| CN111848423B (zh) * | 2019-04-30 | 2022-10-14 | 尚科生物医药（上海）有限公司 | 3-氧代环丁基氨基甲酸叔丁酯的制备方法 |
| CN112110944B (zh) * | 2019-06-21 | 2022-02-11 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和应用 |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| CN112645971B (zh) * | 2021-01-20 | 2021-12-24 | 中国科学院兰州化学物理研究所 | 一种烷基卤代物直接制备烷基硼酸酯类化合物的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9797998A (en) | 1997-10-10 | 1999-05-03 | Trustees Of The University Of Pennsylvania, The | Compositions and methods for inhibiting arginase activity |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| EP1915143A4 (en) | 2005-07-01 | 2009-11-11 | Univ Johns Hopkins | ARGINASE II: TARGET TREATMENT FOR THE AGING HEART AND HEART FAILURE |
| WO2009008415A1 (ja) | 2007-07-12 | 2009-01-15 | Sanyo Denki Co., Ltd. | 二重反転式軸流送風機 |
| TR201910726T4 (tr) * | 2009-01-26 | 2019-08-21 | Astrazeneca Uk Ltd | Arginaz inhibitörleri ve kullanım yöntemleri. |
| BR112012027034B1 (pt) * | 2010-04-22 | 2020-10-13 | Mars, Incorporated | compostos inibidores de arginase, composição farmacêutica compreendendo o referido composto, método in vitro para inibição de arginase i e ii e uso do referido composto |
| CN103402549A (zh) * | 2010-12-31 | 2013-11-20 | 考瑞多制药公司 | 精氨酸酶抑制剂及其使用方法 |
| AU2012326109A1 (en) | 2011-10-19 | 2014-05-29 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
-
2012
- 2012-10-18 AU AU2012326109A patent/AU2012326109A1/en not_active Abandoned
- 2012-10-18 BR BR112014009415-2A patent/BR112014009415B1/pt not_active IP Right Cessation
- 2012-10-18 CN CN201280061312.2A patent/CN104244932B/zh not_active Expired - Fee Related
- 2012-10-18 US US14/352,554 patent/US9266908B2/en active Active
- 2012-10-18 MX MX2014004766A patent/MX343534B/es active IP Right Grant
- 2012-10-18 JP JP2014537234A patent/JP5993459B2/ja active Active
- 2012-10-18 EP EP12781004.2A patent/EP2768491B1/en active Active
- 2012-10-18 WO PCT/US2012/060789 patent/WO2013059437A1/en not_active Ceased
- 2012-10-18 CA CA2852685A patent/CA2852685C/en active Active
-
2014
- 2014-04-13 IL IL232113A patent/IL232113A/en active IP Right Grant